Literature DB >> 23512063

Computed tomography screening for lung cancer.

Phillip M Boiselle1.   

Abstract

IMPORTANCE: Low-dose computed tomography (CT) screening was shown to reduce lung cancer-specific mortality in a large randomized trial of a high-risk population. The decision to pursue CT screening for lung cancer is a timely question raised by individuals at risk of lung cancer and by their health care practitioners.
OBJECTIVES: To discuss the evidence for use of chest x-rays and low-dose CT in screening for lung cancer; to describe potential benefits, harms, and uncertainties of CT screening; and to review current guidelines for CT screening. EVIDENCE REVIEW: MEDLINE and the Cochrane Library were searched from 1984 to 2012. Additional citations were obtained from lists of references from select research and review articles on this topic. Evidence was graded using the American Hospital Association level of evidence guidelines.
FINDINGS: Low-dose CT screening has been associated with a 20% reduction in lung cancer mortality in a large randomized controlled trial (National Lung Screening Trial [NLST]) of a high-risk population. Mortality data have not yet been reported for 5 other randomized controlled trials, and the sample sizes were too small to detect a meaningful difference in 2 other completed trials. A major risk of CT screening is a high false-positive rate, with associated risks and costs associated with follow-up CT scans and the potential for more invasive diagnostic procedures. Published guidelines for screening indicate a consensus that screening may be indicated for individuals who meet entry criteria for the NLST, but some guidelines expand their recommendations for screening beyond these criteria. CONCLUSIONS AND RELEVANCE: Individuals at high risk of lung cancer who meet the criteria for CT screening in published guidelines should participate in an informed and shared decision-making process by discussing the potential benefits, harms, and uncertainties of screening with their physicians.

Entities:  

Mesh:

Year:  2013        PMID: 23512063     DOI: 10.1001/jama.2012.216988

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  28 in total

1.  Initial staging of head and neck squamous cell carcinoma. What is the place of bronchoscopy and upper GI endoscopy?

Authors:  Cyril Page; Emily Lucas-Gourdet; Aurélie Biet-Hornstein; Vladimir Strunski
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-30       Impact factor: 2.503

2.  Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.

Authors:  T Powrózek; P Krawczyk; M Nicoś; B Kuźnar-Kamińska; H Batura-Gabryel; J Milanowski
Journal:  Clin Transl Oncol       Date:  2015-08-27       Impact factor: 3.405

3.  Early detection of lung cancer by using an autoantibody panel in Chinese population.

Authors:  Shengxiang Ren; Shucai Zhang; Tao Jiang; Yayi He; Zhiyong Ma; Hourong Cai; Xiaohong Xu; Yan Li; Weijing Cai; Jing Zhou; Xiaopeng Liu; Xuejun Hu; Jun Zhang; Hui Yu; Caicun Zhou; Fred R Hirsch
Journal:  Oncoimmunology       Date:  2017-10-16       Impact factor: 8.110

4.  Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report.

Authors:  Tomasz Powrózek; Paweł Krawczyk; Tomasz Kucharczyk; Janusz Milanowski
Journal:  Med Oncol       Date:  2014-03-16       Impact factor: 3.064

5.  Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.

Authors:  Hormuzd A Katki; Stephanie A Kovalchik; Lucia C Petito; Li C Cheung; Eric Jacobs; Ahmedin Jemal; Christine D Berg; Anil K Chaturvedi
Journal:  Ann Intern Med       Date:  2018-05-15       Impact factor: 25.391

6.  Lung Cancer Screening Participation: Developing a Conceptual Model to Guide Research.

Authors:  Lisa Carter-Harris; Lorie L Davis; Susan M Rawl
Journal:  Res Theory Nurs Pract       Date:  2016-11-01       Impact factor: 0.688

7.  Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification.

Authors:  Meredith S Shiels; Hormuzd A Katki; Allan Hildesheim; Ruth M Pfeiffer; Eric A Engels; Marcus Williams; Troy J Kemp; Neil E Caporaso; Ligia A Pinto; Anil K Chaturvedi
Journal:  J Natl Cancer Inst       Date:  2015-07-28       Impact factor: 13.506

8.  Targeting of low-dose CT screening according to the risk of lung-cancer death.

Authors:  Anil K Chaturvedi; Hormuzd A Katki; Stephanie A Kovalchik; Martin Tammemagi; Christine D Berg; Neil E Caporaso; Tom L Riley; Mary Korch; Gerard A Silvestri
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

9.  Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials.

Authors:  Daniel M Halperin; J Jack Lee; Cecile Gonzales Dagohoy; James C Yao
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

10.  Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules.

Authors:  Yayi He; Shengxiang Ren; Yan Wang; Xuefei Li; Caicun Zhou; Fred R Hirsch
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.